{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-347524","form_type":"8-K","ticker":"SGMO","cik":"0001001233","company_name":"SANGAMO THERAPEUTICS, INC","filed_at":"2026-08-13T01:36:55+00:00","discovered_at":"2026-08-13T10:10:00.281656+00:00","generated_at":"2026-08-13T10:10:34.042508+00:00","sec_items":["8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Sangamo selects PTC and Lilly as winning bidders in $163.55M asset auction","bullets":["PTC to buy Fabry program (ST-920) for $111M cash + up to $100M milestones ($80M on accelerated approval, $20M on full approval).","Lilly to buy capsid delivery, zinc finger, MINT platforms and prion program (ST-506) for $50M cash.","Tools/equipment sold to various bidders for $2.55M; total cash consideration ~$163.55M.","Sales subject to Bankruptcy Court approval; Lilly close expected ~Sept 4, 2026; PTC close after HSR review.","Company continues to market ST-503, hemophilia A program, cell therapy and T-Reg assets."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-347524","json":"https://secwatch.observer/filing/0001193125-26-347524.json","markdown":"https://secwatch.observer/filing/0001193125-26-347524.md","text":"https://secwatch.observer/filing/0001193125-26-347524.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001233/000119312526347524/0001193125-26-347524-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001233/000119312526347524/d125617d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T10:10:34.042508+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}